Completed PHASE3 INTERVENTIONAL 1-arm NCT00904280

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (Oxymorphone HCL Controlled Release) in Subjects With Cancer Pain or Chronic Lower Back Pain.

Sponsor: Endo Pharmaceuticals

Conditions Cancers, Pain Lower Back Pain

Interventions Oxymorphone ER

Updated 7 times since 2017 Last updated: May 18, 2009 Started: Mar 31, 2001 Primary completion: Jul 31, 2003 Completion: Jul 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00904280, this PHASE3 trial focuses on Cancers, Pain and Lower Back Pain and remains completed. Sponsored by Endo Pharmaceuticals, it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals

Data source: Endo Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tucson, United States